Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sage Therapeutics

7.43
+0.06000.81%
Post-market: 7.450.0200+0.27%17:08 EDT
Volume:616.54K
Turnover:4.59M
Market Cap:456.80M
PE:-1.13
High:7.54
Open:7.33
Low:7.33
Close:7.37
Loading ...

Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating

MT Newswires Live
·
20 Nov 2024

Sage Therapeutics Shares Down 3.7% After Stopping Development of Rare Disease Drug

THOMSON REUTERS
·
20 Nov 2024

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

MT Newswires Live
·
20 Nov 2024

Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Traders Await Nvidia Earnings

MT Newswires Live
·
20 Nov 2024

BUZZ-Sage Therapeutics declines after stopping development of rare disease drug

Reuters
·
20 Nov 2024

SAGE Therapeutics: Hold Rating Amid Strategic Shift Following Dalzanemdor Discontinuation

TIPRANKS
·
20 Nov 2024

Sage Therapeutics to end Huntington's disease trial after key therapy fails again

Dow Jones
·
20 Nov 2024

Sage slips as Huntington’s Disease therapy fails in mid-stage trial

seekingalpha
·
20 Nov 2024

SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints

MT Newswires Live
·
20 Nov 2024

Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again

Dow Jones
·
20 Nov 2024

Sage Therapeutics Shares Down 18.5% Premarket After Co's Rare Disease Drug Fails to Meet Main Goal in Mid-Stage Study

THOMSON REUTERS
·
20 Nov 2024

Sage Therapeutics' stock slides after trial of Huntington's Disease treatment fails and company says it will end it

Dow Jones
·
20 Nov 2024

Sage Therapeutics' rare disease drug fails mid-stage study

Reuters
·
20 Nov 2024

Sage Therapeutics reports results from Phase 2 DIMENSION Study

TIPRANKS
·
20 Nov 2024

BRIEF-Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718)

Reuters
·
20 Nov 2024

Sage Therapeutics Inc - to Halt Further Development of Dalzanemdor

THOMSON REUTERS
·
20 Nov 2024

Sage Therapeutics - to Close Ongoing Purview Study, an Open-Label Safety Study of Dalzanemdor in Participants With Hd

THOMSON REUTERS
·
20 Nov 2024

Sage Therapeutics Inc - Dalzanemdor Did Not Meet Primary Endpoint in Phase 2 Study

THOMSON REUTERS
·
20 Nov 2024

Sage Therapeutics Announces Topline Results From the Phase 2 Dimension Study of Dalzanemdor (Sage-718) in the Treatment of Cognitive Impairment Associated With Huntington’s Disease

THOMSON REUTERS
·
20 Nov 2024

Sage Therapeutics Inc - Dalzanemdor Generally Well-Tolerated With No New Safety Signals

THOMSON REUTERS
·
20 Nov 2024